Cargando…
Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma
BACKGROUND: Accumulated evidence highlights the significance of the crosstalk between epigenetic and epitranscriptomic mechanisms, notably 5-methylcytosine (5mC) and N(6)-methyladenosine (m(6)A). Herein, we conducted a widespread analysis regarding the crosstalk between 5mC and m(6)A regulators in h...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830866/ https://www.ncbi.nlm.nih.gov/pubmed/36627693 http://dx.doi.org/10.1186/s12943-022-01706-6 |
_version_ | 1784867754548920320 |
---|---|
author | Tian, Yu Xiao, Haijuan Yang, Yanhui Zhang, Pingping Yuan, Jiahui Zhang, Wei Chen, Lijie Fan, Yibao Zhang, Jinze Cheng, Huan Deng, Tingwei Yang, Lin Wang, Weiwei Chen, Guoyong Wang, Peiqin Gong, Peng Niu, Xing Zhang, Xianbin |
author_facet | Tian, Yu Xiao, Haijuan Yang, Yanhui Zhang, Pingping Yuan, Jiahui Zhang, Wei Chen, Lijie Fan, Yibao Zhang, Jinze Cheng, Huan Deng, Tingwei Yang, Lin Wang, Weiwei Chen, Guoyong Wang, Peiqin Gong, Peng Niu, Xing Zhang, Xianbin |
author_sort | Tian, Yu |
collection | PubMed |
description | BACKGROUND: Accumulated evidence highlights the significance of the crosstalk between epigenetic and epitranscriptomic mechanisms, notably 5-methylcytosine (5mC) and N(6)-methyladenosine (m(6)A). Herein, we conducted a widespread analysis regarding the crosstalk between 5mC and m(6)A regulators in hepatocellular carcinoma (HCC). METHODS: Pan-cancer genomic analysis of the crosstalk between 5mC and m(6)A regulators was presented at transcriptomic, genomic, epigenetic, and other multi-omics levels. Hub 5mC and m(6)A regulators were summarized to define an epigenetic and epitranscriptomic module eigengene (EME), which reflected both the pre- and post-transcriptional modifications. RESULTS: 5mC and m(6)A regulators interacted with one another at the multi-omic levels across pan-cancer, including HCC. The EME scoring system enabled to greatly optimize risk stratification and accurately predict HCC patients’ clinical outcomes and progression. Additionally, the EME accurately predicted the responses to mainstream therapies (TACE and sorafenib) and immunotherapy as well as hyper-progression. In vitro, 5mC and m(6)A regulators cooperatively weakened apoptosis and facilitated proliferation, DNA damage repair, G2/M arrest, migration, invasion and epithelial-to-mesenchymal transition (EMT) in HCC cells. The EME scoring system was remarkably linked to potential extrinsic and intrinsic immune escape mechanisms, and the high EME might contribute to a reduced copy number gain/loss frequency. Finally, we determined potential therapeutic compounds and druggable targets (TUBB1 and P2RY4) for HCC patients with high EME. CONCLUSIONS: Our findings suggest that HCC may result from a unique synergistic combination of 5mC-epigenetic mechanism mixed with m(6)A-epitranscriptomic mechanism, and their crosstalk defines therapeutic response and pharmacogenomic landscape. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01706-6. |
format | Online Article Text |
id | pubmed-9830866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98308662023-01-11 Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma Tian, Yu Xiao, Haijuan Yang, Yanhui Zhang, Pingping Yuan, Jiahui Zhang, Wei Chen, Lijie Fan, Yibao Zhang, Jinze Cheng, Huan Deng, Tingwei Yang, Lin Wang, Weiwei Chen, Guoyong Wang, Peiqin Gong, Peng Niu, Xing Zhang, Xianbin Mol Cancer Research BACKGROUND: Accumulated evidence highlights the significance of the crosstalk between epigenetic and epitranscriptomic mechanisms, notably 5-methylcytosine (5mC) and N(6)-methyladenosine (m(6)A). Herein, we conducted a widespread analysis regarding the crosstalk between 5mC and m(6)A regulators in hepatocellular carcinoma (HCC). METHODS: Pan-cancer genomic analysis of the crosstalk between 5mC and m(6)A regulators was presented at transcriptomic, genomic, epigenetic, and other multi-omics levels. Hub 5mC and m(6)A regulators were summarized to define an epigenetic and epitranscriptomic module eigengene (EME), which reflected both the pre- and post-transcriptional modifications. RESULTS: 5mC and m(6)A regulators interacted with one another at the multi-omic levels across pan-cancer, including HCC. The EME scoring system enabled to greatly optimize risk stratification and accurately predict HCC patients’ clinical outcomes and progression. Additionally, the EME accurately predicted the responses to mainstream therapies (TACE and sorafenib) and immunotherapy as well as hyper-progression. In vitro, 5mC and m(6)A regulators cooperatively weakened apoptosis and facilitated proliferation, DNA damage repair, G2/M arrest, migration, invasion and epithelial-to-mesenchymal transition (EMT) in HCC cells. The EME scoring system was remarkably linked to potential extrinsic and intrinsic immune escape mechanisms, and the high EME might contribute to a reduced copy number gain/loss frequency. Finally, we determined potential therapeutic compounds and druggable targets (TUBB1 and P2RY4) for HCC patients with high EME. CONCLUSIONS: Our findings suggest that HCC may result from a unique synergistic combination of 5mC-epigenetic mechanism mixed with m(6)A-epitranscriptomic mechanism, and their crosstalk defines therapeutic response and pharmacogenomic landscape. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01706-6. BioMed Central 2023-01-10 /pmc/articles/PMC9830866/ /pubmed/36627693 http://dx.doi.org/10.1186/s12943-022-01706-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Tian, Yu Xiao, Haijuan Yang, Yanhui Zhang, Pingping Yuan, Jiahui Zhang, Wei Chen, Lijie Fan, Yibao Zhang, Jinze Cheng, Huan Deng, Tingwei Yang, Lin Wang, Weiwei Chen, Guoyong Wang, Peiqin Gong, Peng Niu, Xing Zhang, Xianbin Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma |
title | Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma |
title_full | Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma |
title_fullStr | Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma |
title_full_unstemmed | Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma |
title_short | Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma |
title_sort | crosstalk between 5-methylcytosine and n(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830866/ https://www.ncbi.nlm.nih.gov/pubmed/36627693 http://dx.doi.org/10.1186/s12943-022-01706-6 |
work_keys_str_mv | AT tianyu crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT xiaohaijuan crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT yangyanhui crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT zhangpingping crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT yuanjiahui crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT zhangwei crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT chenlijie crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT fanyibao crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT zhangjinze crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT chenghuan crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT dengtingwei crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT yanglin crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT wangweiwei crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT chenguoyong crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT wangpeiqin crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT gongpeng crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT niuxing crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma AT zhangxianbin crosstalkbetween5methylcytosineandn6methyladenosinemachinerydefinesdiseaseprogressiontherapeuticresponseandpharmacogenomiclandscapeinhepatocellularcarcinoma |